SCHEMBL6077418

SCHEMBL6077418

NCc1cc(Cl)ccc1-c1nsnc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.38
LOXL2 Q9Y4K0 1/20 0.34
DPP4 P27487 12/20 0.33
CYP3A4 P08684 2/20 0.32
MAPT P10636 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
POLB P06746 1/20 0.32
DPP8 Q6V1X1 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MGAM O43451 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
SI P14410 1/20 0.31
RAB9A P51151 1/20 0.31
MGAM2 Q2M2H8 1/20 0.31
PNMT P11086 1/20 0.31
SLC22A1 O15245 1/20 0.31
USP2 O75604 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6077459 0.84 CRHR1 (0.32) CYP3A4MAPTMEN1KMT2ASLC22A1
SCHEMBL6078239 0.75 NOTUM (0.42) CYP2A6CYP3A4MAPTMEN1KMT2A
SCHEMBL6919231 0.73 CYP2A6 (0.41) CYP2A6LOXL2DPP4CYP3A4MAPT
SCHEMBL3806613 0.67 DPP4 (0.40) LOXL2DPP4CYP3A4KDM4EGAA
SCHEMBL6079066 0.67 CYP2A6 (0.41) CYP2A6LOXL2DPP4CYP3A4MAPT
SCHEMBL701343 0.66 CYP2A6 (0.48) CYP2A6LOXL2CYP3A4MAPTMEN1
SCHEMBL8935466 0.65 KDM4E (0.41) CYP2A6MAPTKMT2AKDM4EMGAM
SCHEMBL28764594 0.65 DPP4 (0.43) DPP4MEN1KMT2ADPP8LMNA
SCHEMBL10983827 0.65 IDO1 (0.45) DPP4KDM4EALDH1A1GAARAB9A
SCHEMBL42557 0.64 PNMT (0.52) CYP2A6DPP4CYP3A4MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7144899-B2 Thrombin inhibitors MERCK & CO., INC. (US) 2006-12-05 US disclosed
US-20040073025-A1 Thrombin inhibitors MERCK SHARP & DOHME CORP. 2004-04-15 US disclosed
WO-2002064559-A2 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040073025-A1 Thrombin inhibitors F2, F11, F10 CYP2A6 2106/4885LOXL2 4054/4885DPP4 3046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.